Fertil Steril：子宫内膜异位症药物治疗新进展

  摘要：

  Endometriosis affects 1 in 10 women of reproductive-age. The current treatments are surgical and hormonal but have limitations, including the risk of recurrence, side effects, contraceptive action for women who desire pregnancy, and cost. New treatments include gonadotropin-releasing hormone analogues, selective progesterone (or estrogen) receptor modulators, aromatase inhibitors, immunomodulators , and antiangiogenic agents. 

       子宫内膜异位症影响着十分之一的育龄妇女。目前治疗方法为手术治疗和激素替代治疗，但有一定的局限性，其中包括复发风险，副作用，避孕措施以及成本等。新治疗方式包括促性腺激素释放激素类似物，选择性孕激素（或雌激素）受体调节剂，酶抑制剂，免疫调节抑制剂和抗血管生成素。

    Endometriosis, a chronic and recurrent disease, represents a challenge to health-care providers and a burden on the health care system.The reported prevalence of endometriosis is between 2% and 10% in the general population, 50% in the infertile population (1, 2), and more than 60% in patients with chronic pelvic pain (CPP) (3).

       子宫内膜异位症是一种慢性和复发性疾病，对医护人员来说是一种挑战。同时，也是医疗系统的一项负担。据报道，子宫内膜异位症患病率在正常人群中为2％至10％之间，不孕人群中约为50％（1,2），慢性盆腔疼痛（CPP）患者约超过60％（3）。

    Further research is needed into central sensitization, localneurogenesis, and the genetics of endometriosis to identify additionaltreatment targets. A wider range of medical options allows for the possibilityof precision health and a more personalized treatment approach for women withendometriosis.

       我们需要进一步研究中枢敏感性和子宫内膜异位症的遗传学，从而探索更多的治疗方向。医疗方案广泛性应该允许精准医学和对子宫内膜异位症妇女采取个性化的治疗方案。